Category: Capitol Hill
Ohio-based medical device makers meet with local legislators to discuss efforts to repeal the upcoming 2.3% levy while the National Republican Congressional Committee uses the tax to target Democrats in upcoming Congressional races.
The medical device industry's efforts to repeal an impending 2.3% tax on sales continue to run in high gear as Ohio's med-tech industry discusses impacts with local legislators and a Congressional GOP group takes the rhetoric and runs with it.
By Merrill Goozner
Over the angry protests of consumer groups, Congress is moving rapidly – and in bipartisan fashion – to give drug and medical device companies an easier path to Food and Drug Administration approval for some products in exchange for sharply higher user fees to fund the agency.
Senators Charles Grassley and Herb Kohl, co-authors and co-sponsors of the Sunshine Act, have issued a statement in response to the announcement made by the Centers for Medicare and Medicaid Services. Last week, CMS posted a notice that it will not require data collection by applicable manufacturers and applicable group purchasing organizations (GPOs) pursuant to the Sunshine Act before January 1, 2013.
A GPO asks the IRS to ban device makers from baking the cost of the med-tech tax in product price hikes, a House panel speeds the FDA user fee bill to the next stage and Covidien jumps into the renal denervation market with CE Mark in hand.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
The FDA's medical device user fee agreements overcome GOP clamor and push toward approval in both houses of Congress as legislators hope to pass the bill before election season.
FDA user fee agreements are set to march toward approval without much partisan squabbling as members of Congress hope to avoid the political quicksand that accompanies election season.
A U.S. House version of a bill reauthorizing FDA user fees for medical devices and pharmaceuticals, posted just before the weekend, is heading toward approval without some of the controversial language that threatened to leave the bill in a partisan quagmire.
Medtronic's CRM layoffs may be a sign of a prolonged slump; Johnson & Johnson might be eyeing Edwards or St. Jude; Edwards wins CMS Medicare coverage for its Sapien TAVI system; Masimo CEO Kiani tells us why the med-tech industry should protect its young; GOP govs ask Senate and House leaders to kill the medical device tax; MassDevice.com looks at the most talked about device makers in April; and Siemens reveals probes into Russian payments and its diagnostics business.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.
By Merrill Goozner
What's in a name? Everything, it would appear, when it comes to describing Rep. Paul Ryan's plan to privatize Medicare, which the Republican-controlled House of Representatives backed in its budget resolution late last month. The plan would subsidize seniors' purchase of private insurance plans instead of enrolling in traditional government-financed Medicare, although that would be preserved as an option. The government would finance a portion of the purchase.
